Article

Targeting anoikis resistance in prostate cancer metastasis

Department of Surgery/Urology, University of Kentucky College of Medicine, Lexington, KY, USA.
Molecular Aspects of Medicine (Impact Factor: 10.3). 02/2010; 31(2):205-14. DOI: 10.1016/j.mam.2010.02.001
Source: PubMed

ABSTRACT Anoikis is a mode of apoptotic cell death, consequential to insufficient cell-matrix interactions and a critical player in tumor angiogenesis and metastasis. The events involved in tumor cell progression toward metastasis potential are mediated by integrins, which upon engagement with components of the extracellular matrix (ECM), reorganize to form adhesion complexes. Targeting apoptotic players is of immense therapeutic significance since resistance to apoptosis is not only critical in conferring therapeutic failure to standard treatment strategies, but anoikis (apoptosis upon loss of anchorage and detachment from ECM) also plays an important role in angiogenesis and metastasis. The ability to survive in the absence of adhesion to the ECM, enables tumor cells to disseminate from the primary tumor site, invade a distant site and establish a metastatic lesion. Tumor cells can escape from detachment-induced apoptosis by controlling anoikis pathways, including the extrinsic death receptor pathway and the ECM-integrin mediated cell survival pathway. Considering the functional promiscuity of individual signaling effectors, it is critical to dissect the molecular networks mechanistically driving tumor cells to evade anoikis and embark on a metastatic spread. Resistance to die via anoikis dictates tumor cell survival and provides a molecular basis for therapeutic targeting of metastatic prostate cancer. Further dissection of critical anoikis signaling events will enable the therapeutic optimization of anoikis targeting to impair prostate cancer metastasis prior to its initiation. This review will discuss the molecular understanding of anoikis regulation in the tumor microenvironment and the in vivo pharmacological implementation of a novel class of antitumor-drugs to optimize apoptotic-based therapeutic targeting, bypassing anoikis-resistance to impair prostate cancer progression to metastasis. Potential combination strategies targeting tumor vascularity (via anoikis) and impairing tumor initiation (via "classic" apoptosis), provide strong therapeutic promise for metastatic prostate cancer by preventing the onset of metastasis.

Download full-text

Full-text

Available from: Shinichi Sakamoto, Aug 14, 2015
0 Followers
 · 
114 Views
  • Source
    • "The Bcl-2 protein as one of the Bcl-2 family proteins regulates cytochrome c release from the mitochondria and prevents apoptotic cell death (Plati et al., 2011). Down-regulation of Bax and up-regulation of Bcl-2 in many drug-resistant tumor cells has been reported (Sakamoto and Kyprianou, 2010). In Chronic Myeloid Leukemia (CML) cells, overexpression of Bcl-2 protein and association with Bcr/Abl cause accelerated transfer rate of chronic phase to blastic phase (Tzifi et al., 2011) and leads to tumor progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Spiroquinazolinone compounds have been considered as a new series of potent apoptosis-inducing agents. In this study, anti-proliferative and apoptotic effects of the derivatives from the spiroquinazolinone family were investigated in the human chronic myeloid leukemia K562 cells. The K562 cells were treated with various concentrations of the spiroquinazolinone (10-300 µM) for 3 days and cell viability was determined by MTT growth inhibition assay. 4t-QTC was more active among these compounds with IC50 of 50 ± 3.6 µM and was selected for further studies. Apoptosis, as the mechanism of cell death was investigated morphologically by acridine orange/ethidium bromide (AO/EtBr) double staining, cell surface expression assay of phosphatidyl serine by Annexin V/PI technique, as well as the formation of DNA ladder. The K562 cells underwent apoptosis upon a single dose (at IC50 value) of the 4t-QTC compound, and over-expressed caspase-3 expression by more than 1.7-fold, following a 72 hr treatment. Furthermore, RT-PCR and Western blot analysis revealed that treatment of the K562 cells with 4t-QTC down-regulates and up-regulates the expression of Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic), respectively. Based on the present data, it seems that these compounds from the spiroquinazolinone family are good candidates for further evaluation as an effective chemotherapeutic family acting through induction of apoptosis in chronic myeloid leukemia.
    The Journal of Toxicological Sciences 01/2015; 40(1):115-126. DOI:10.2131/jts.40.115 · 1.38 Impact Factor
  • Source
    • "The Bcl-2 protein as one of the Bcl-2 family proteins regulates cytochrome c release from the mitochondria and prevents apoptotic cell death (Plati et al., 2011). Down-regulation of Bax and up-regulation of Bcl-2 in many drug-resistant tumor cells has been reported (Sakamoto and Kyprianou, 2010). In Chronic Myeloid Leukemia (CML) cells, overexpression of Bcl-2 protein and association with Bcr/Abl cause accelerated transfer rate of chronic phase to blastic phase (Tzifi et al., 2011) and leads to tumor progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT — Spiroquinazolinone compounds have been considered as a new series of potent apoptosis-inducing agents. In this study, anti-proliferative and apoptotic effects of the derivatives from the spiroquinazolinone family were investigated in the human chronic myeloid leukemia K562 cells. The K562 cells were treated with various concentrations of the spiroquinazolinone (10-300 μM) for 3 days and cell viability was determined by MTT growth inhibition assay. 4t-QTC was more active among these compounds with IC50 of 50 ± 3.6 μM and was selected for further studies. Apoptosis, as the mechanism of cell death was investigated morphologically by acridine orange/ethidium bromide (AO/EtBr) double staining, cell surface expression assay of phosphatidyl serine by Annexin V/PI technique, as well as the formation of DNA ladder. The K562 cells underwent apoptosis upon a single dose (at IC50 value) of the 4t-QTC compound, and over-expressed caspase-3 expression by more than 1.7-fold, following a 72 hr treatment. Furthermore, RT-PCR and Western blot analysis revealed that treatment of the K562 cells with 4t-QTC down-regulates and up-regulates the expression of Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic), respectively. Based on the present data, it seems that these compounds from the spiroquinazolinone family are good candidates for further evaluation as an effective chemotherapeutic family acting through induction of apoptosis in chronic myeloid leukemia.
    The Journal of Toxicological Sciences 12/2014; 40(1):115-126. · 1.38 Impact Factor
  • Source
    • "Pathophysiologically, resistance to anoikis is acquired in epithelial cancer cells due to gene expression or activity abnormality, which allows cancer cells to survive in an anchorage-independent manner when deprived of extracellular matrix attachment during dissemination in blood or lymph, and associated with metastatic spread of cancer cells [2]. Anoikis has been suggested as a potential target for anticancer therapy [3] [4]. Hepatocarcinoma is one of the most frequent malignancies and remains the third leading cause of cancer death worldwide [5] [6] [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anoikis has been recognized as a potential target for anticancer therapy. Polygonum cuspidatum (Huzhang) is a frequently used Chinese herb in hepatocarcinoma. In present study, we evaluated the effects of Polygonum cuspidatum extract (PCE) in hepatocarcinoma cells in suspension. The results showed that PCE inhibited the proliferation of hepatocarcinoma cells in suspension in a dose- and time-dependent manner. PCE also inhibited anchorage-independent growth of hepatocarcinoma cells in soft agar. PCE induced anoikis in human hepatocarcinoma Bel-7402 cells accompanied by caspase-3 and caspase-9 activation and poly(ADP-ribose) polymerase cleavage, which was completely abrogated by a pan caspase inhibitor, Z-VAD-FMK. In addition, PCE treatment induced intracellular reactive oxygen species (ROS) production in Bel-7402 cells. NAC, an ROS scavenger, partially attenuated PCE-induced anoikis and activation of caspase-3 and caspase-9. Furthermore, PCE inhibited expression of focal adhesion kinase (FAK) in Bel-7402 cells. Overexpression of FAK partially abrogated PCE-induced anoikis. These data suggest that PCE may inhibit suspension growth and induce caspase-mediated anoikis in hepatocarcinoma cells and may relate to ROS generation and FAK downregulation. The present study provides new insight into the application of Chinese herb for hepatocarcinoma treatment.
    Evidence-based Complementary and Alternative Medicine 09/2012; 2012:607675. DOI:10.1155/2012/607675 · 1.88 Impact Factor
Show more